Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07370532
Recruiting Phase 2

Etoricoxib in Patients With Parkinsonian Disease

NCT07370532 · tracked via the Priya Life Science Egypt tracker
Sponsor
Ihab Elsayed Hassan
Phase
Phase 2
Started
2026-01-30
Last updated
2026-04-08

Condition(s) studied

Parkinson Disease

Investigational drug(s) / intervention(s)

L-dopa →Etoricoxib →

L-dopa: Levodopa is the standard therapy in PD.

Etoricoxib: Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.

Study summary

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Eligibility

Sex
ALL
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale. Exclusion Criteria: * Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications * Pregnant women and women with planned pregnancy. * Patients who are currently using other anti-inflammatory drugs.

Primary outcome measure(s)

  • - Change in The Unified Parkinson's Disease Rating Scale — 6 months
    \- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

Trial sites (1)

FacilityCityRegionStatus
Mansoura University Al Mansurah Egypt Recruiting

More Ihab Elsayed Hassan trials in Egypt

Pentoxifylline in Patients With Ulcerative Colitis Recruiting

Other trials for the same condition

Vinpocetine in Patients With Parkinsonian Disease Recruiting
Metformin in Parkinson Disease Recruiting
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease Recruiting
Fexofenadine as Adjuvant Therapy in Parkinson Disease Recruiting
6 Month Follow up Study on the Changes of Postural Stability in Parkinsonian Patients in Response to High Frequency TMS. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07370532 on ClinicalTrials.gov ↗ ← All trials in Egypt